Jump to content



Recommended Posts

As to timing of the "Big Bang" my train of thought is nothing will happen til the bulk of the US reporting season is over.


Check out SLA on the back of the ANP news.


Lets hope I'm wrong on this one. They may wish to squeeze it in before everyone else has to show just how bad things really are. Give everyone a safe haven to go to.

Link to comment
Share on other sites

  • Replies 10k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

Bridges and La Loanshark clearly have absolutely no intent on creating any value in the SP until the transaction occurs. No wonder SM scarpered. ANP looking much better when you compare ISIS to ALNY. Relevant stocks in this sector in Japan going absolutely mental today and yesterday. Hitting their stops almost instantly. Something leaking if you ask me.
Link to comment
Share on other sites

drafter, you will have to elaborate on the significance of the Bayer presence. UMass is obviously looking after US interests.


Bayer are due to get a new CEO on Oct 01. He wouldn't be getting on board if he didn't think things were going to be resolved by then.

Link to comment
Share on other sites

part of the strategic alliance csiro have with bayer crop science is my guess - ref csiro web info.


the re-statement of interested parties in the declaration doesn't have any material impact on the

interference proceeding, until such time as it may get declared in favour of csiro/bayer. Then it's

impact will be a bigger care factor.


Bayer could provide more financial clout for Waterhouse patent prosecutions i guess, not that csiro

patent guys would need it these days.



Link to comment
Share on other sites

Bayer is described as an exclusive licensee. I thought that was Benitec for human health and ag. stayed with CSIRO.


Stranger too is that Bayer have been all over PGL.


I can't understand why in any documentation anywhere, including archives of the trials they sponsored, Benitec no longer exists except in the ASX quotes. They don't have an office, everything is done off a cell phone and invoices get sent to Peter Francis' office. Kinda like a drug dealer ring. But you can still buy the stock and Bridges says they aren't for sale making it necessary for a new CEO on a quarter mill. sponsored by La Jolla. What sort of crock is this? Makes Whitton look like God.


My money is moving in to ANP.

Link to comment
Share on other sites

My money is moving in to ANP.


i'd take a step back plastic to look at the bigger

picture of what's been put on the table.


following hiv study results (which 3 years ago none

of us could have known for sure were going to go

so well), i'm actually feeling pretty underdone.


also Henry McKusker is based in the states - he mentions

Benitec very clearly in his blog, and so does John Zaia.


i'm pretty confident this study result will have made more than

one big pharma sit up and take notice of blt. And best thing is,

we've already got all the patents we need for a commercial


Link to comment
Share on other sites

Benitec receives US patent


As Benitec and CSIRO prepare for a re-examination of some Graham ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢099 patent claims by the US Patents and Trademarks Office in August, the partners have received encouraging news that the Graham-derived plant and animal gene expression patent has been granted US protection.


Benitec chief executive Peter French described the patent as ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“another brick in the wallÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ in terms of the ddRNAi Graham family patent protection, and told BTN it followed a pattern established in other markets, where patent protection for continuations had been received.


French said the USPTO grant was a step towards re-establishing BenitecÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s US-based patent position.


The CSIRO patent application 10/646,070 was issued a notice of allowance on January 27 and was granted the patent number 7754697.


Benitec holds an exclusive worldwide licence to the ddRNAi technology in human applications, while CSIRO retains animal, plant and other rights.


CSIRO also has the rights to commercialise research tools and research services based on the technology (limited by existing exclusive rights in the Sigma-Aldrich licence). It has, however, agreed to pay Benitec 50% of the net revenues from the commercialisation of these.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...